TWB Annual report 2022

TWB celebrated its 10th anniversary and recorded its best results ever: revenue of €12 million (compared to €9 million in 2021), a 40% increase in the number of industrial contracts signed, and 40 new industrial projects launched. The TWB consortium has welcomed two new members: the Lyon-based start-up Bon Vivant and the Canadian industrial group Premier Tech.

TWB - Bioprocess Platform - Cytometry serviceice cytométrie

Bioprocess Platform – Cytometry service


The turnover includes 5.7 M€ of industrial contracts (5.3 M€ in 2021 and 2.9 M€ in 2020) and 3.6 M€ of subsidies, including 1.4 M€ of ANR funding (France 2030). Industrial contracts represented 61% of the 88 projects (R&D and services) – including 49 new ones – carried out by TWB in 2022.

Integrated offerings with Processium and Syngulon

Two new service offerings were introduced in partnerhsip with innovative start-ups from the TWB consortium : Processium and Syngulon. This broadens the range of TWB services and enhances the integrated offerings already provided. TWB invested almost €2.5 million in equipment to diversify its services, acquire news functionalities and boost the performance of its platforms.

Diversyfying into new markets

TWB has capitalised on its expertise to branch out into another field of application : ingredients, where industrial biotechnologies provide a solution to the market’s needs and challenges. This expansion was achieved through two new consortium members : Lyon-based Bon Vivant and the Canadian industrial group Premier Tech. In addition, the Toulouse Industrial Biotechnology for Health (TIBH) industrial integrator had its certification renewed for five years as part of the ANR Biotherapeutics-Bioproduction Integrators call for proposals process.